In that study, the cancer risk reduction from GLP-1R agonist use was comparable to that from lifestyle intervention (16% risk reduction; ref. 29) and bariatric surgery (32% risk reduction; ref. 30); however, some evidence suggests anticancer benefits of GLP-1R therapies beyond weight loss. Here, GLP1R is linked to cancer.